91422
document
Incidence and clinical significance of false-negative sextant prostate biopsies . PURPOSE Since most patients do not undergo repeat sextant prostate biopsies after a biopsy is positive for prostate cancer , the true incidence of false-negative biopsies is not well defined . We assess the incidence and clinical significance of false-negative sextant prostate biopsies in patients undergoing radical prostatectomy . MATERIALS AND METHODS A total of 118 patients with biopsy proved prostate cancer underwent repeat sextant prostate biopsy before enrollment in a prospective randomized trial of radical prostatectomy with or without neoadjuvant hormonal therapy . Clinical parameters were assessed to determine potential sources of bias . Pathological parameters and prostate specific antigen relapse-free survival rates were compared to determine the clinical significance of false-negative biopsies . RESULTS Of the 118 patients 27 ( 23 % ) had a negative repeat sextant biopsy . Except for initial clinical stage , no differences were noted in the clinical or pathological parameters , or prostate specific antigen relapse rates in patients with negative versus positive repeat biopsies . CONCLUSIONS Our findings suggest that this 23 % incidence of false-negative biopsies represents significant cancer . This relatively high incidence is important to consider in treatment modalities in which prostate biopsy may be performed to determine response to therapy .
91423
Intervention_Surgical
radical prostatectomy
91424
Intervention_Surgical
radical prostatectomy
91425
Intervention_Physical
neoadjuvant hormonal therapy
91426
Outcome_Adverse-effects
prostate specific antigen relapse-free survival rates
91427
Outcome_Physical
clinical or pathological parameters
91428
Outcome_Physical
prostate specific antigen relapse rates